Contemporary adrenal scintigraphy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 4, 2007, Pages 547-557

  Gross, Milton D ^a,b   Avram, Anca ^a   Fig, Lorraine M ^a,b   Rubello, Domenico ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Adrenal; Adrenocortical; Adrenomedullary; Radiopharmaceutical; Scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; 6 IODOCHOLESTEROL I 131; 6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; ACETIC ACID C 11; ADRENALIN C 11; AMINOIODOBENZYLGUANIDINE I 131; CONTRAST MEDIUM; ETOMIDATE C 11; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F 18; FLUORODOPAMINE F 18; HYDROXYEPINEPHRINE C 11; IODOCHOLESTEROL I 131; LIPID; LOW DENSITY LIPOPROTEIN I 123; LOW DENSITY LIPOPROTEIN I 131; LOW DENSITY LIPOPROTEIN IN 111; LOW DENSITY LIPOPROTEIN TC 99M; METOMIDATE C 11; METYRAPONE I 131; PENTETREOTIDE I 123; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SELENOMETHYLNORCHOLESTEROL SE 75; SOMATOSTATIN DERIVATIVE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL PEPTIDE I 123;

ADRENAL CORTEX; ADRENAL DISEASE; ADRENAL GLAND; ADRENAL INCIDENTALOMA; ADRENAL MEDULLA; ADRENAL MEDULLA DISEASE; ADRENAL SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DIAGNOSTIC IMAGING; EVALUATION; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY HYPERALDOSTERONISM; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADRENAL GLAND DISEASES; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; PHYSICIAN'S PRACTICE PATTERNS; RADIONUCLIDE IMAGING; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33947279874     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0265-5     Document Type: Review

References (49)

1. Gross MD, Korobkin M, Hussain H, et al. Adrenal gland imaging. In: Jameson JL, DeGroot LJ, editors. Endocrinology, 5th edn. Philadelphia: Saunders; 2005; p. 2425-53.
2. Gross MD, Rubello D, Shapiro B. Is there a future for adrenal scintigraphy? Nucl Med Commun 2002;23:197-202.
3. Gross MD, Shapiro B, Bui C, Shulkin B, Sisson J. Adrenal scintigraphy and metaiodobenzylguanidine therapy of neuroendocrine tumors. In: Sandler MP, Coleman RE, Patton JA, Wackers FJT, Gottschalk A, editors. Diagnostic nuclear medicine, 4th edn. Philadelphia: Lippincott Williams and Wilkins; 2003; p. 715-34.
4. Gross MD, Bui C, Shapiro B. Adrenocortical scintigraphy. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment, 3rd edn. Edinburgh: Churchill and Livingstone; 2004; p. 45-52.
5. Avram A, Fig LM, Gross MD. Nuclear imaging of the adrenal gland. Semin Nucl Med 2006;36:212-27.
6. Eriksson B, Bergström M, Sundin A, Juhlin C, Örlefors H, Öberg K, et al. The role of PET in the localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002;970:159-69.
7. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med 2004;48:150-63.
8. Kainberger F, Kurtaran A, Keinast O, Dobrozemsky G, Czerny C, Kletter K. Hybrid imaging for endocrine diseases: new perspectives. Weiner Klin Wochen 2003;115 (Suppl 2):87-90.
9. Gross MD, Valk TW, Thrall JH, Beierwaltes WH. The role of pharmacologic manipulation in adrenal cortical scintigraphy. Semin Nucl Med 1981;11:128-48.
10. Gross MD, Shapiro, B. Scintigraphic studies in adrenal hypertension. Semin Nucl Med 1990;19:122-43.
11. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568-80.
12. 18F-FDG. J Nucl Med 2004;45:972-9.
13. 11C-metomidate. Eur J Nucl Med Mol Imaging 2004;31:1224-30.
14. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-7.
15. Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002;147(1):13-28.
16. Gross MD, Shapiro B, Shreve P. Radionuclide imaging of the adrenal cortex. Q J Nucl Med 1999;43:224-32.
17. Ilias I, Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 2004;1018:495-504.
18. 123I]- metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006;27(1):31-6.
19. 111In-octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93.
20. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytomas. Trends Endocrinol Metab 2001;12:469-75.
21. Eriksson B, Bergström M, Sundin A, Juhlin C, Örlefors H, Öberg K, et al. The role of PET in the localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002;970:159-69.
22. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795-9.
23. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006;47:32-7.
24. Sohaib SA, Hanson JA, Reznek RH, Trainer PJ, Monson JP, Grossman AB, et al. CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing syndrome. Am J Roentgenol AJR 1999;172:997-1002.
25. Schteingart DE, Seabold JE, Gross MD, Swanson D. Iodocholesterol adrenal tissue uptake and imaging in adrenal neoplasms. J Clin Endocrinol Metab 1981;52:1156-62.
26. Fig LM, Ehrmann D, Gross MD, Shapiro B, Schteingart D, Glazer D. The localization of abnormal adrenal function in the ACTH-independent Cushing syndrome. Ann Intern Med 1988;109:547-53.
27. 11C-metomidate imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 2003;30:403-10.
28. 11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 2006;91:1410-4.
29. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumors? Preliminary results in 13 consecutive patients. Eur J Endocrinol 2004;150:789-92.
30. Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy? J Endocrinol Invest 2004;27:387-99.
31. Rao SK, Caride VJ, Ponn R, Giakovis E, Lee SH. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med 2004;29(5):300-2.
32. 18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing's syndrome. Ann Nucl Med 2003;17(5):403-6.
33. Frilling A, Tecklenborg K, Weber F, Kühl H, Müller S, Stamatis G, et al. Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery 2004;136:1289-96.
34. Kloos RT, Gross MD, Francis IR. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460-84.
35. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. Am J Roentgenol AJR 1998;171:201-4.
36. Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005;234:479-85.
37. Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab 2005;19:277-92.
38. Sahdev A, Reznek RH. Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends Endocrinol Metab 2004;15:272-6.
39. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. Am J Roentgenol AJR 1998;170:747-52.
40. Outwater EK, Siegelman ES, Radecki PD, Piccoli CW, Mitchell DG. Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. A J Roentgenol AJR 1995;165:579-83.
41. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 2004;42:884-92.
42. Maurea S, Caraco C, Klain M, Mainolfi M, Salvatore M. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques. Q J Nucl Med Mol Imaging 2004;48:188-97.
43. Francis IR, Korobkin M. Pheochromocytoma. Radiol Clin North Am 1996;34:1101-12.
44. Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 2005;37:717-21.
45. Shapiro B, Sisson J, Kalff V, Glowniak J, Satterlee W, Glazer G, et al. The location of middle mediastinal pheochromocytomas. J Thorac Cardiovasc Surg 1984;87:814-20.
46. Hay RV, Gross MD. Scintigraphic imaging of the adrenals and neuroectodermal tumors. In: Henkin RE, Bova D, Karesh SM, Dillehey GL, Wagner RH, Halama JR, Zimmer AM, editors. Nuclear medicine, 2nd edn. Philadelphia: Mosby; 2006; p. 820-44.
47. Ilias I, Shulkin B, Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastoma and ganglioneuromas. Trends Endocrinol Metab 2005;16:66-72.
48. 11C hydroxyephedrine PET. Radiology 2004;230:423-8.
49. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003;88:4083-7.